Archives

Get the latest industry insights.

Quality people. Great service. Responsive. Professional.

Tag: Clinical News

Clinical Catch-Up: December 11-17

Clinical Catch-Up: December 11-17

Via: https://www.biospace.com/article/clinical-catch-up-december-11-17/ Published: Dec 20, 2021 By Mark Terry It was an enormously busy week with plenty of announcements from the American Society of Hematology (ASH) meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look: COVID-19-Related

Read More »
New Study Finds Freenome’s Multiomics Approach Successful in Detecting Pancreatic Cancer

New Study Finds Freenome’s Multiomics Approach Successful in Detecting Pancreatic Cancer

Via: https://www.biospace.com/article/releases/new-study-finds-freenome-s-multiomics-approach-successful-in-detecting-pancreatic-cancer/ Published: Sep 29, 2021 SOUTH SAN FRANCISCO, Calif., Sept. 29, 2021 /PRNewswire/ — Freenome, a privately-held biotech company, presented new research today at the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer. The data demonstrated the potential of extending Freenome’s multiomics approach into other

Read More »
Now Hiring

Clinical Catch-Up: July 12-16

Published: Jul 19, 2021 By Mark Terry Via: https://www.biospace.com/article/clinical-catch-up-july-12-16/ It was a moderately busy mid-summer week for clinical trial news. Here’s a look. COVID-19-Related ARCA biopharma provided an update on its Phase IIb ASPEN-COVID-19 trial of rNAPc2 for hospitalized COVID-19 patients. It has received approval from regulators

Read More »
Clinical Catch-Up: January 10-14

Roche Presents Positive Clinical Data for Neurology Programs at EAN Annual Meeting

via: https://www.biospace.com/article/roche-presents-positive-clinical-data-for-neurology-programs-at-ean-annual-meeting/ Roche presented results from several Phase II and III trials at the 7th Congress of the European Academy of Neurology (EAN) Annual Meeting held virtually June 19-22. Some of the results specifically underscored the efficacy and safety of EVRYSDI™ (risdiplam) for motor neuron disease, Enspryng® (satralizumab)

Read More »